VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
PSNL
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
PSNLPersonalis, Inc.
$13.02$1.2B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksPSNLBalance Sheet

Personalis, Inc. (PSNL) Balance Sheet

9Y historyFree accessUpdated daily

The company's liquidity buffer is under significant pressure, with cash reserves falling from $124.2 million in 2025Q4 to $73.6 million in 2026Q1, despite maintaining a modest debt-to-equity ratio of 0.12.

PSNL Balance Sheet

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17
Total Current Assets258.2M267.95M203.01M146.74M199.7M318.23M220.72M139.58M29.56M26.73M
Cash & Short-Term Investments233.22M239.95M185.01M114.18M167.66M287.06M203.29M128.29M19.74M22.62M
Cash Only73.59M124.25M91.42M56.98M89.13M105.58M68.53M55.05M19.74M22.62M
Short-Term Investments159.62M115.71M93.59M57.2M78.53M181.48M134.76M73.24M00
Accounts Receivable13.02M16.2M8.14M17.73M16.64M18.47M6.35M3.3M4.46M1.94M
Days Sales Outstanding75.75-35.1188.0793.3878.8529.4718.4743.0775.27
Inventory6.93M6.14M3.98M5.66M6.38M4.08M2.67M1.42M2.13M822K
Days Inventory Outstanding35.0341.6325.1137.3845.0727.6716.6812.0529.9925.56
Other Current Assets5.03M5.65M5.89M9.17M9.02M1.53M2.96M3.18M1.3M542K
Total Non-Current Assets67.2M66.21M67.25M78.36M93M78.3M24.12M17.71M12.11M6.84M
Property, Plant & Equipment63.4M59.93M64.73M75.22M88.42M73.47M22.11M15.95M11.45M6.34M
Fixed Asset Turnover1.04x-1.31x0.98x0.74x1.16x3.56x4.09x3.30x1.48x
Goodwill0000000000
Intangible Assets0000000000
Long-Term Investments0000000000
Other Non-Current Assets3.8M6.28M2.53M3.14M4.59M4.83M2.02M1.76M659K495K
Total Assets325.39M334.16M270.27M225.1M292.7M396.53M244.84M157.29M41.67M33.56M
Asset Turnover0.22x-0.31x0.33x0.22x0.22x0.32x0.41x0.91x0.28x
Asset Growth %83.38%23.64%20.07%-23.1%-26.18%61.95%55.66%277.47%24.15%-
Total Current Liabilities39.05M39.63M31.13M47.23M33.13M31.31M40.64M49.96M57.85M48.99M
Accounts Payable12.68M12.99M6.4M14.92M12.85M9.22M8.3M7.34M6.57M4.04M
Days Payables Outstanding76.6288.0140.498.5390.7562.5251.7662.192.27125.49
Short-Term Debt001.67M1.65M2.22M1.81M005M17.51M
Deferred Revenue (Current)1.63M03.1M3.29M1.29M4.36M21.03M35.98M42.9M24.71M
Other Current Liabilities26.37M26.64M10.86M19.62M9.55M11.19M8.45M4.39M43.18M718K
Current Ratio6.61x6.76x6.52x3.11x6.03x10.16x5.43x2.79x0.51x0.55x
Quick Ratio6.44x6.61x6.39x2.99x5.83x10.03x5.37x2.77x0.47x0.53x
Cash Conversion Cycle34.16-19.8226.9347.744-5.62-31.57-19.21-24.66
Total Non-Current Liabilities31.59M33.35M36.19M48.42M41.43M54.91M9.26M639K90.21M77.18M
Long-Term Debt31.02M31.87M000000683K292K
Capital Lease Obligations66.05M034.88M38.32M41.04M52.8M8.54M639K00
Deferred Tax Liabilities0000000000
Other Non-Current Liabilities562K1.48M1.3M10.1M389K2.12M720K089.53M76.89M
Total Liabilities70.63M72.98M67.31M95.66M74.56M86.23M49.9M50.6M148.06M126.17M
Total Debt31.02M31.87M44.25M47.73M48.65M58.33M10.99M2M5M17.51M
Net Debt-42.57M-92.38M-47.17M-9.26M-40.48M-47.25M-57.54M-53.05M-14.75M-5.11M
Debt / Equity0.12x0.12x0.22x0.37x0.22x0.19x0.06x0.02x--
Debt / EBITDA-0.33x---------
Net Debt / EBITDA0.46x---------
Interest Coverage-609.71x-395.34x-3385.08x-982.75x-562.56x-353.41x-20610.50x-21.13x-9.50x-17.11x
Total Equity254.76M261.19M202.96M129.44M218.14M310.3M194.94M106.69M-106.39M-92.6M
Equity Growth %124.32%28.69%56.79%-40.66%-29.7%59.17%82.72%200.28%-14.89%-
Book Value per Share2.452.933.432.694.777.075.675.92-4.89-4.26
Total Shareholders' Equity254.76M261.19M202.96M129.44M218.14M310.3M194.94M106.69M-106.39M-92.6M
Common Stock10K10K9K5K5K4K4K3K1K1K
Retained Earnings-661.29M-631.26M-549.99M-468.71M-360.41M-247.09M-181.87M-140.59M-115.5M-95.62M
Treasury Stock00000000-9.13M-3.02M
Accumulated OCI-70K104K-23K-222K-912K-166K22K-6K-15K-10K
Minority Interest0000000000

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Liquidity and capital exhaustion

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Eroding Equity Base Signals Distress

As reported in recent financial filings, Personalis has seen its total equity decline from $261.2 million in 2025Q4 to $254.8 million in 2026Q1, a trend that reflects the persistent accumulation of retained losses and underscores a weakening balance sheet trajectory as the company struggles to reach scale.

The consistent expansion of the accumulated deficit, now reaching $661.3 million, suggests that the company's business model has yet to achieve the necessary operating leverage to offset its high fixed-cost base. Investors should monitor whether this erosion of equity continues to outpace potential capital raises, as it may indicate a narrowing window for the company to achieve commercial viability.

Leverage Remains Modest but Constrained

According to the latest quarterly balance sheet, the company maintains a debt-to-equity ratio of 0.12, a figure that appears deceptively low given the underlying cash burn and the limited operational flexibility inherent in the current capital structure as reported in recent SEC filings.

While the absolute debt level of $31.0 million is relatively small, the company's inability to generate positive operating cash flow makes even this modest leverage a potential burden on liquidity. The reliance on debt in a pre-profit state warrants caution, as it may limit the company's ability to secure additional financing on favorable terms if the current cash burn persists.

Liquidity Buffer Faces Significant Pressure

Based on the provided financial data, cash reserves dropped sharply from $124.2 million in 2025Q4 to $73.6 million in 2026Q1, indicating a rapid depletion of the company's primary liquidity buffer that may necessitate further capital market activity to sustain ongoing research and development operations.

Although the current ratio of 6.61 appears robust on the surface, this metric is heavily influenced by the composition of current assets and does not account for the high cash-burn rate observed in recent quarters. The significant decline in cash over a single quarter suggests that the company's runway is shortening, which may force management to prioritize capital preservation over strategic growth initiatives.

Hidden Risks in Asset Composition

As evidenced by the balance sheet, the company's asset base is heavily concentrated in property, plant, and equipment, with $63.4 million in net PPE, which may represent a significant impairment risk if the company fails to achieve the projected utilization rates for its sequencing infrastructure.

The lack of goodwill on the balance sheet is a positive indicator of conservative accounting, yet the high concentration of fixed assets in a contracting revenue environment suggests that these assets may be underutilized. Investors should consider the potential for future asset write-downs if the transition to clinical diagnostics does not materialize as expected, which would further impair the company's book value.

PSNL — Frequently Asked Questions

Quick answers to the most common questions about buying PSNL stock.

What are the total assets of Personalis, Inc. (PSNL)?

As of 2025, Personalis, Inc. (PSNL) had total assets of $334.2M including $268.0M in current assets.

How much debt does Personalis, Inc. (PSNL) have?

Personalis, Inc. (PSNL) carries total debt of $31.9M, offset by $240.0M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Personalis, Inc.?

Personalis, Inc. (PSNL) has total shareholders' equity (book value) of $261.2M ($2.93 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Personalis, Inc.'s current ratio and liquidity?

Personalis, Inc. (PSNL) reported a current ratio of 6.76x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.